Apyx Medical (NASDAQ:APYX) Stock Price Up 1.5% - Here's What Happened

Key Points

• Apyx Medical shares increased by 1.5% during mid-day trading, reaching a high of $2.19 before closing at $2.09.
• The company reported quarterly earnings of ($0.09) per share, meeting expectations despite a negative net margin of 37.11% and a PE ratio of -4.64.
• Institutional investors own 55.33% of Apyx Medical's stock, with notable acquisitions by firms such as Nantahala Capital Management and Citadel Advisors LLC.

Apyx Medical Corporation (NASDAQ:APYX - Get Free Report)'s share price rose 1.5% on Friday . The stock traded as high as $2.19 and last traded at $2.09. Approximately 36,763 shares were traded during mid-day trading, a decline of 67% from the average daily volume of 110,911 shares. The stock had previously closed at $2.06.

Apyx Medical Price Performance

The company has a quick ratio of 3.95, a current ratio of 4.72 and a debt-to-equity ratio of 4.61. The company has a market cap of $75.83 million, a price-to-earnings ratio of -4.46 and a beta of 1.39. The company has a fifty day simple moving average of $2.13 and a two-hundred day simple moving average of $1.59.

Apyx Medical (NASDAQ:APYX - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.09) earnings per share for the quarter, meeting the consensus estimate of ($0.09). The company had revenue of $11.37 million for the quarter, compared to analyst estimates of $11.69 million. Apyx Medical had a negative return on equity of 158.22% and a negative net margin of 37.11%. Apyx Medical has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that Apyx Medical Corporation will post -0.68 earnings per share for the current fiscal year.

Institutional Trading of Apyx Medical

A number of large investors have recently made changes to their positions in APYX. Geode Capital Management LLC boosted its stake in shares of Apyx Medical by 7.5% during the fourth quarter. Geode Capital Management LLC now owns 352,809 shares of the company's stock valued at $558,000 after acquiring an additional 24,596 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Apyx Medical during the fourth quarter valued at $134,000. Northern Trust Corp boosted its stake in shares of Apyx Medical by 27.9% during the fourth quarter. Northern Trust Corp now owns 132,251 shares of the company's stock valued at $209,000 after acquiring an additional 28,865 shares during the last quarter. Citadel Advisors LLC boosted its stake in shares of Apyx Medical by 130.6% during the fourth quarter. Citadel Advisors LLC now owns 66,355 shares of the company's stock valued at $105,000 after acquiring an additional 37,582 shares during the last quarter. Finally, Silverberg Bernstein Capital Management LLC boosted its stake in Apyx Medical by 13.2% in the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 646,569 shares of the company's stock worth $886,000 after buying an additional 75,337 shares during the last quarter. Institutional investors and hedge funds own 55.33% of the company's stock.

Apyx Medical Company Profile

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures.